can cancer patients take glutathione Glutathione: Lights and Shadows in Glutamine Supplementation as an Anticancer

Antisense oligonucleotides (ASOs) Basics and principles ASOs, initially established as a therapeutic strategy by Stephenson And Zamecnik in 1978, are synthetic entities capable of modulating the expression of nearly any RNA target, providing a versatile and promising therapeutic option

Additionally, it was shown that UPF1 is not degraded by -glutamyltranspeptidase, which performs glutathione breakdown

doi: 10.3389/fnut.2026.1695902 Received 30 August 2025 Revised 13 January 2026 Accepted 26 January 2026 Published 19 February 2026 Volume 13 - 2026 Edited by Yemin Wang, University of British Columbia, Canada Reviewed by Afreen Saif, King George Medical University, India Le Anh Minh Nguyen, Western University, Canada Jianan Geng, Jilin Agriculture University, China Updates Copyright 2026 Zhang, Xu, Wang, Shen, Sun, Zha and Wang

P.PazziM.ZeppaG